Immuneering Statistics
Total Valuation
Immuneering has a market cap or net worth of $285.32 million. The enterprise value is $81.66 million.
| Market Cap | 285.32M |
| Enterprise Value | 81.66M |
Important Dates
The last earnings date was Friday, May 15, 2026, before market open.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immuneering has 64.70 million shares outstanding. The number of shares has increased by 62.73% in one year.
| Current Share Class | 64.70M |
| Shares Outstanding | 64.70M |
| Shares Change (YoY) | +62.73% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 13.76% |
| Owned by Institutions (%) | 41.71% |
| Float | 49.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.38 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 32.45, with a Debt / Equity ratio of 0.02.
| Current Ratio | 32.45 |
| Quick Ratio | 31.50 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -43.84% and return on invested capital (ROIC) is -28.90%.
| Return on Equity (ROE) | -43.84% |
| Return on Assets (ROA) | -27.89% |
| Return on Invested Capital (ROIC) | -28.90% |
| Return on Capital Employed (ROCE) | -28.23% |
| Weighted Average Cost of Capital (WACC) | 6.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$989,812 |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +142.31% in the last 52 weeks. The beta is 0.38, so Immuneering's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | +142.31% |
| 50-Day Moving Average | 5.08 |
| 200-Day Moving Average | 5.79 |
| Relative Strength Index (RSI) | 45.89 |
| Average Volume (20 Days) | 2,484,287 |
Short Selling Information
The latest short interest is 12.72 million, so 19.67% of the outstanding shares have been sold short.
| Short Interest | 12.72M |
| Short Previous Month | 9.89M |
| Short % of Shares Out | 19.67% |
| Short % of Float | 25.74% |
| Short Ratio (days to cover) | 8.75 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -59.23M |
| Pretax Income | -54.44M |
| Net Income | -54.44M |
| EBITDA | -58.88M |
| EBIT | -59.23M |
| Earnings Per Share (EPS) | -$1.06 |
Balance Sheet
The company has $156.69 million in cash and $3.73 million in debt, with a net cash position of $194.91 million or $3.01 per share.
| Cash & Cash Equivalents | 156.69M |
| Total Debt | 3.73M |
| Net Cash | 194.91M |
| Net Cash Per Share | $3.01 |
| Equity (Book Value) | 206.52M |
| Book Value Per Share | 3.19 |
| Working Capital | 156.43M |
Cash Flow
In the last 12 months, operating cash flow was -$49.70 million and capital expenditures -$213,211, giving a free cash flow of -$49.91 million.
| Operating Cash Flow | -49.70M |
| Capital Expenditures | -213,211 |
| Depreciation & Amortization | 349,925 |
| Net Borrowing | n/a |
| Free Cash Flow | -49.91M |
| FCF Per Share | -$0.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immuneering does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -62.73% |
| Shareholder Yield | -62.73% |
| Earnings Yield | -19.68% |
| FCF Yield | -18.05% |
Analyst Forecast
The average price target for Immuneering is $17.00, which is 285.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.00 |
| Price Target Difference | 285.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |